{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:03:31Z","timestamp":1790737411892,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,1,18]],"date-time":"2011-01-18T00:00:00Z","timestamp":1295308800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s11926-011-0163-0","type":"journal-article","created":{"date-parts":[[2011,1,17]],"date-time":"2011-01-17T11:00:58Z","timestamp":1295262058000},"page":"138-145","source":"Crossref","is-referenced-by-count":18,"title":["Role of Melanocortin Receptors in the Regulation of Gouty Inflammation"],"prefix":"10.1007","volume":"13","author":[{"given":"Trinidad","family":"Montero-Melendez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hetal B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Perretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,1,18]]},"reference":[{"key":"163_CR1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrrheum.2009.236","volume":"6","author":"R Terkeltaub","year":"2010","unstructured":"\u2022\u2022 Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010;6:30\u20138. This is an excellent state-of-the-art review that covers the pathogenesis of gout as well as therapeutic options. Updated to include the latest developments, it is a must read for experts as well as novices in the area.","journal-title":"Nat Rev Rheumatol"},{"key":"163_CR2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11926-001-0049-7","volume":"3","author":"RC Landis","year":"2001","unstructured":"Landis RC, Haskard DO. Pathogenesis of crystal-induced inflammation. Curr Rheumatol Rep 2001;3:36\u201341.","journal-title":"Curr Rheumatol Rep"},{"key":"163_CR3","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"HR Schumacher Jr","year":"2008","unstructured":"Schumacher HR, Jr., et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008;59:1540\u20138.","journal-title":"Arthritis Rheum"},{"key":"163_CR4","first-page":"710","volume":"46","author":"HN Leopold","year":"1950","unstructured":"Leopold HN. ACTH and colchicine in therapy of gout; report of a case of acute gouty arthritis. Tex State J Med 1950;46:710\u20132.","journal-title":"Tex State J Med"},{"key":"163_CR5","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","volume":"62","author":"RA Terkeltaub","year":"2010","unstructured":"\u2022\u2022 Terkeltaub RA, et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 2010;62:1060\u20138. This is an important clinical study that validates the use of low-dose colchicine in gout, observing significant disease control with a much lower burden of side effects. The conclusion reached in the study may have direct implications for the management of disease among many gouty patients.","journal-title":"Arthritis Rheum"},{"key":"163_CR6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nrd1034","volume":"2","author":"RJ Flower","year":"2003","unstructured":"Flower RJ. The development of COX2 inhibitors. Nat Rev Drug Discov 2003;2:179\u201391.","journal-title":"Nat Rev Drug Discov"},{"key":"163_CR7","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/S0140-6736(08)60799-0","volume":"371","author":"HJ Janssens","year":"2008","unstructured":"Janssens HJ, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008;371:1854\u201360.","journal-title":"Lancet"},{"key":"163_CR8","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.tips.2009.01.001","volume":"30","author":"JL Wallace","year":"2009","unstructured":"\u2022\u2022 Wallace JL, et al. Cyclooxygenase-inhibiting nitric oxide donators for osteoarthritis. Trends Pharmacol Sci 2009;30:112\u20137. This is a state-of-the art review on the development of novel anti-inflammatory therapeutics, with emphasis on the lower degree of side effects they cause, as well as on the efficacy in joint disease. These compounds could be useful for the control of gout.","journal-title":"Trends Pharmacol Sci"},{"key":"163_CR9","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1476-5381.2009.00611.x","volume":"159","author":"JL Wallace","year":"2010","unstructured":"\u2022 Wallace JL, et al. Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Br J Pharmacol 2010;159:1236\u201346. This was an important study on a novel anti-inflammatory derivative of naproxen, based on the controlled release of hydrogen sulfide, that could lead to a new class of therapeutics.","journal-title":"Br J Pharmacol"},{"key":"163_CR10","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon F, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237\u201341.","journal-title":"Nature"},{"key":"163_CR11","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/ard.2009.108936","volume":"68","author":"R Terkeltaub","year":"2009","unstructured":"\u2022 Terkeltaub R, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009;68:1613\u20137. This fundamental clinical investigation supports the pivotal role played by IL-1 in gout. This would open the door to other strategies aiming at blockade of release and\/or effects of this cytokine.","journal-title":"Ann Rheum Dis"},{"key":"163_CR12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0025-6196(24)00526-3","volume":"24","author":"PS Hench","year":"1949","unstructured":"Hench PS, et al. The effect of the adrenal cortex (17-hydroxy-11-dehydrocortisone: compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis; preliminary report. Proc Staff Meet Mayo Clin 1949;24:181\u201397.","journal-title":"Proc Staff Meet Mayo Clin"},{"key":"163_CR13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/0002-9343(50)90004-0","volume":"9","author":"AB Gutman","year":"1950","unstructured":"Gutman AB, Yu TF. Effects of adrenocorticotropic hormone (ACTH) in gout. Am J Med 1950;9:24\u201330.","journal-title":"Am J Med"},{"key":"163_CR14","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/00003495-200868040-00002","volume":"68","author":"N Schlesinger","year":"2008","unstructured":"\u2022\u2022 Schlesinger N. Overview of the management of acute gout and the role of adrenocorticotropic hormone. Drugs 2008;68:407\u201315. This is an excellent review on the application of ACTH in gout. There is more to this hormone that could be exploited for novel antigout approaches. It is highly relevant to the topic of this article.","journal-title":"Drugs"},{"key":"163_CR15","first-page":"696","volume":"21","author":"J Ritter","year":"1994","unstructured":"Ritter J, et al. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol 1994;21:696\u20139.","journal-title":"J Rheumatol"},{"key":"163_CR16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2007-0027","volume":"29","author":"T Brzoska","year":"2008","unstructured":"\u2022\u2022 Brzoska T, et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev 2008;29:581\u2013602. This is a detailed and competent review on the MC pathway, summarizing biochemical synthesis, biological properties, and therapeutic potential. It is an updated summary on the anti-inflammatory and tissue-protective properties of MC peptides.","journal-title":"Endocr Rev"},{"key":"163_CR17","doi-asserted-by":"crossref","first-page":"E468","DOI":"10.1152\/ajpendo.00434.2002","volume":"284","author":"I Gantz","year":"2003","unstructured":"Gantz I, Fong TM. The melanocortin system. Am J Physiol Endocrinol Metab 2003;284:E468\u201374.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"163_CR18","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.4049\/jimmunol.161.6.2873","volume":"161","author":"SK Manna","year":"1998","unstructured":"Manna SK, Aggarwal BB. Alpha-melanocyte-stimulating hormone inhibits the nuclear transcription factor NF-kappa B activation induced by various inflammatory agents. J Immunol 1998;161:2873\u201380.","journal-title":"J Immunol"},{"key":"163_CR19","doi-asserted-by":"crossref","unstructured":"Eves PC, Haycock JW. Melanocortin signalling mechanisms. In: Catania A, editor. Melanocortins Multiple actions and therapeutic potential Landes Bioscience, 2009. p. 19\u201327.","DOI":"10.1007\/978-1-4419-6354-3_2"},{"key":"163_CR20","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1002\/art.10526","volume":"46","author":"SJ Getting","year":"2002","unstructured":"Getting SJ, et al. Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum 2002;46:2765\u201375.","journal-title":"Arthritis Rheum"},{"key":"163_CR21","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1100\/tsw.2009.163","volume":"9","author":"SJ Getting","year":"2009","unstructured":"\u2022 Getting SJ, et al. Melanocortin peptide therapy for the treatment of arthritic pathologies. ScientificWorldJournal 2009;9:1394\u2013414. This review states the potential for therapeutics based on the MC system for pathologies of the joint, including gout. It is an excellent summary.","journal-title":"ScientificWorldJournal"},{"key":"163_CR22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/79254","volume":"26","author":"AS Chen","year":"2000","unstructured":"Chen AS, et al. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat Genet 2000;26:97\u2013102.","journal-title":"Nat Genet"},{"key":"163_CR23","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1096\/fj.10-167759","volume":"24","author":"HB Patel","year":"2010","unstructured":"\u2022\u2022 Patel HB, et al. Anti-inflammatory and antiosteoclastogenesis properties of endogenous melanocortin receptor type 3 in experimental arthritis. FASEB J 2010, 24:4835\u20134843. This is the first study demonstrating a pro-resolving\/anti-inflammatory function for endogenous MC 3 in the context of experimental joint disease. Data presented here also reveal novel properties for ligands to this receptor in the context of osteoclast generation.","journal-title":"FASEB J"},{"key":"163_CR24","doi-asserted-by":"crossref","first-page":"8246","DOI":"10.1016\/S0021-9258(18)53088-X","volume":"268","author":"I Gantz","year":"1993","unstructured":"Gantz I, et al. Molecular cloning of a novel melanocortin receptor. J Biol Chem 1993;268:8246\u201350.","journal-title":"J Biol Chem"},{"key":"163_CR25","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0092-8674(00)80467-5","volume":"91","author":"W Chen","year":"1997","unstructured":"Chen W, et al. Exocrine gland dysfunction in MC5-R-deficient mice: evidence for coordinated regulation of exocrine gland function by melanocortin peptides. Cell 1997;91:789\u201398.","journal-title":"Cell"},{"key":"163_CR26","first-page":"53","volume":"52","author":"AW Taylor","year":"2006","unstructured":"Taylor AW, et al. Melanocortin 5 receptor and ocular immunity. Cell Mol Biol (Noisy-le-grand) 2006;52:53\u20139.","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"163_CR27","doi-asserted-by":"crossref","unstructured":"\u2022 Patel HB, et al. Melanocortin control of cell trafficking in vascular inflammation. In: Catania A, editor. Melanocortins: Multiple actions and therapeutic potential Landes Bioscience, 2009. p. 88\u2013102. This is a summary of the pharmacology of MC receptors and their agonists in experimental models of inflammation and tissue injury. It also covers some of the efforts produced by Biotech and pharmaceutical companies to develop novel therapeutics based on this line of research.","DOI":"10.1007\/978-1-4419-6354-3_7"},{"key":"163_CR28","first-page":"559","volume":"78","author":"A Matsukawa","year":"1998","unstructured":"Matsukawa A, et al. Analysis of the cytokine network among tumor necrosis factor alpha, interleukin-1beta, interleukin-8, and interleukin-1 receptor antagonist in monosodium urate crystal-induced rabbit arthritis. Lab Invest 1998;78:559\u201369.","journal-title":"Lab Invest"},{"key":"163_CR29","doi-asserted-by":"crossref","unstructured":"Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment. Arthritis Res Ther 2006;8 Suppl 1:S3.","DOI":"10.1186\/ar1908"},{"key":"163_CR30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/icb.2009.93","volume":"88","author":"R Liu-Bryan","year":"2010","unstructured":"\u2022\u2022 Liu-Bryan R. Intracellular innate immunity in gouty arthritis: role of NALP3 inflammasome. Immunol Cell Biol 2010;88:20\u20133. This important article summarizes the importance of the inflammasome in gouty arthritis. Important links with autoinflammatory disease can be derived, sharing also IL-1 blockade as an efficient strategy for innovative therapy.","journal-title":"Immunol Cell Biol"},{"key":"163_CR31","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.0105-2896.2009.00851.x","volume":"233","author":"Y Shi","year":"2010","unstructured":"\u2022 Shi Y, et al. Monosodium urate crystals in inflammation and immunity. Immunol Rev 2010;233:203\u201317. This is a competent and well-written review that presents an updated summary on the pathology of gout, including the intracellular events associated with the inflammasome.","journal-title":"Immunol Rev"},{"key":"163_CR32","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1002\/art.27456","volume":"62","author":"HM Hoffman","year":"2010","unstructured":"\u2022\u2022 Hoffman HM, et al. Role of the leucine-rich repeat domain of cryopyrin\/NALP3 in monosodium urate crystal-induced inflammation in mice. Arthritis Rheum 2010;62:2170\u20139. In this elegant article, cryopyrin leucine-rich repeat deletion mutant mice are generated to highlight the essential requirement of the leucine-rich domain for caspase-1 activation and IL-1\u03b2 release in macrophages.","journal-title":"Arthritis Rheum"},{"key":"163_CR33","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1002\/art.20317","volume":"50","author":"DR Yagnik","year":"2004","unstructured":"Yagnik DR, et al. Macrophage release of transforming growth factor beta1 during resolution of monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2004;50:2273\u201380.","journal-title":"Arthritis Rheum"},{"key":"163_CR34","doi-asserted-by":"crossref","first-page":"7446","DOI":"10.4049\/jimmunol.162.12.7446","volume":"162","author":"SJ Getting","year":"1999","unstructured":"Getting SJ, et al. POMC gene-derived peptides activate melanocortin type 3 receptor on murine macrophages, suppress cytokine release, and inhibit neutrophil migration in acute experimental inflammation. J Immunol 1999;162:7446\u201353.","journal-title":"J Immunol"},{"key":"163_CR35","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/1529-0131(199805)41:5<900::AID-ART18>3.0.CO;2-K","volume":"41","author":"R Terkeltaub","year":"1998","unstructured":"Terkeltaub R, et al. The murine homolog of the interleukin-8 receptor CXCR-2 is essential for the occurrence of neutrophilic inflammation in the air pouch model of acute urate crystal-induced gouty synovitis. Arthritis Rheum 1998;41:900\u20139.","journal-title":"Arthritis Rheum"},{"key":"163_CR36","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1002\/art.24846","volume":"60","author":"S Grassel","year":"2009","unstructured":"\u2022\u2022 Grassel S, et al. The melanocortin system in articular chondrocytes: melanocortin receptors, pro-opiomelanocortin, precursor proteases, and a regulatory effect of alpha-melanocyte-stimulating hormone on proinflammatory cytokines and extracellular matrix components. Arthritis Rheum 2009;60:3017\u201327. This was a fundamental study demonstrating MC functions in chondrocytes; description of receptor expression is complemented by in vitro analyses of anabolic effects upon MC peptide addition to human chondrocytes.","journal-title":"Arthritis Rheum"},{"key":"163_CR37","doi-asserted-by":"crossref","first-page":"E1181","DOI":"10.1152\/ajpendo.00412.2002","volume":"284","author":"J Cornish","year":"2003","unstructured":"Cornish J, et al. alpha-melanocyte-stimulating hormone is a novel regulator of bone. Am J Physiol Endocrinol Metab 2003;284:E1181\u201390.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"163_CR38","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1136\/ard.2009.109355","volume":"68","author":"R Torres","year":"2009","unstructured":"\u2022 Torres R, et al. Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis. Ann Rheum Dis 2009;68:1602\u20138. This was an important preclinical study assessing the pathogenic pathways activated by urate crystals to promote inflammatory disease.","journal-title":"Ann Rheum Dis"},{"key":"163_CR39","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.4049\/jimmunol.170.6.3323","volume":"170","author":"SJ Getting","year":"2003","unstructured":"Getting SJ, et al. Redundancy of a functional melanocortin 1 receptor in the anti-inflammatory actions of melanocortin peptides: studies in the recessive yellow (e\/e) mouse suggest an important role for melanocortin 3 receptor. J Immunol 2003;170:3323\u201330.","journal-title":"J Immunol"},{"key":"163_CR40","doi-asserted-by":"crossref","first-page":"R151","DOI":"10.1186\/ar2827","volume":"11","author":"F Capsoni","year":"2009","unstructured":"\u2022 Capsoni F, et al. Melanocortin peptides inhibit urate crystal-induced activation of phagocytic cells. Arthritis Res Ther 2009;11:R151. The findings of this study illustrate the inhibitory activity of MC peptides on monocyte production of chemotactic factors and subsequent neutrophil responses to these chemotactic factors in MSU crystal\u2013induced inflammation.","journal-title":"Arthritis Res Ther"},{"key":"163_CR41","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1189\/jlb.69.1.98","volume":"69","author":"SJ Getting","year":"2001","unstructured":"Getting SJ, et al. Natural and synthetic agonists of the melanocortin receptor type 3 possess anti-inflammatory properties. J Leukoc Biol 2001;69:98\u2013104.","journal-title":"J Leukoc Biol"},{"key":"163_CR42","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1124\/mol.106.028878","volume":"70","author":"SJ Getting","year":"2006","unstructured":"Getting SJ, et al. [D-Trp8]-gamma-melanocyte-stimulating hormone exhibits anti-inflammatory efficacy in mice bearing a nonfunctional MC1R (recessive yellow e\/e mouse). Mol Pharmacol 2006;70:1850\u20135.","journal-title":"Mol Pharmacol"},{"key":"163_CR43","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1096\/fj.06-6339com","volume":"20","author":"SJ Getting","year":"2006","unstructured":"Getting SJ, et al. Melanocortin 3 receptors control crystal-induced inflammation. FASEB J 2006;20:2234\u201341.","journal-title":"FASEB J"},{"key":"163_CR44","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1096\/fj.08-113886","volume":"22","author":"G Leoni","year":"2008","unstructured":"Leoni G, et al. Inflamed phenotype of the mesenteric microcirculation of melanocortin type 3 receptor-null mice after ischemia-reperfusion. Faseb J 2008;22:4228\u201338.","journal-title":"Faseb J"},{"key":"163_CR45","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejphar.2005.12.023","volume":"532","author":"SJ Getting","year":"2006","unstructured":"Getting SJ, et al. The melanocortin peptide HP228 displays protective effects in acute models of inflammation and organ damage. Eur J Pharmacol 2006;532:138\u201344.","journal-title":"Eur J Pharmacol"},{"key":"163_CR46","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1124\/jpet.103.051623","volume":"306","author":"SJ Getting","year":"2003","unstructured":"Getting SJ, et al. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther 2003;306:631\u20137.","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-011-0163-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-011-0163-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-011-0163-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T21:36:11Z","timestamp":1740864971000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-011-0163-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,18]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["163"],"URL":"https:\/\/doi.org\/10.1007\/s11926-011-0163-0","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,18]]}}}